Biogen Inc.
BIIB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,675,900 | $9,835,600 | $10,173,400 | $10,981,700 |
| % Growth | -1.6% | -3.3% | -7.4% | – |
| Cost of Goods Sold | $2,310,400 | $2,533,400 | $2,278,300 | $2,109,700 |
| Gross Profit | $7,365,500 | $7,302,200 | $7,895,100 | $8,872,000 |
| % Margin | 76.1% | 74.2% | 77.6% | 80.8% |
| R&D Expenses | $2,488,500 | $2,702,600 | $2,597,000 | $3,400,500 |
| G&A Expenses | $2,319,900 | $2,430,900 | $2,354,900 | $2,581,400 |
| SG&A Expenses | $2,386,700 | $2,502,300 | $2,409,000 | $2,680,100 |
| Sales & Mktg Exp. | $66,800 | $71,400 | $54,100 | $98,700 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,875,200 | $5,204,900 | $5,006,000 | $6,080,600 |
| Operating Income | $2,490,300 | $2,097,300 | $2,889,100 | $2,791,400 |
| % Margin | 25.7% | 21.3% | 28.4% | 25.4% |
| Other Income/Exp. Net | -$584,300 | -$800,500 | $705,300 | -$1,011,300 |
| Pre-Tax Income | $1,906,000 | $1,296,800 | $3,594,400 | $1,780,100 |
| Tax Expense | $273,800 | $135,300 | $632,800 | $52,500 |
| Net Income | $1,632,200 | $1,161,100 | $3,046,900 | $1,556,100 |
| % Margin | 16.9% | 11.8% | 29.9% | 14.2% |
| EPS | 11.2 | 8.02 | 20.97 | 10.44 |
| % Growth | 39.7% | -61.8% | 100.9% | – |
| EPS Diluted | 11.19 | 7.97 | 20.87 | 10.4 |
| Weighted Avg Shares Out | 145,700 | 144,700 | 145,300 | 149,100 |
| Weighted Avg Shares Out Dil | 145,900 | 145,600 | 146,000 | 149,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $67,600 | $276,500 | $89,300 | $11,000 |
| Interest Expense | $250,300 | $246,900 | $246,600 | $253,600 |
| Depreciation & Amortization | $673,200 | $494,800 | $518,400 | $487,700 |
| EBITDA | $2,995,700 | $2,377,000 | $3,536,900 | $3,923,400 |
| % Margin | 31% | 24.2% | 34.8% | 35.7% |